Related references
Note: Only part of the references are listed.Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?
Lucas W. Thornblade et al.
SURGERY (2021)
The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5
Oana Popa et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
Kirstine Nielsen et al.
BMC CANCER (2020)
Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?
Andrew M. Bellizzi
HUMAN PATHOLOGY (2020)
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
James R. Howe et al.
PANCREAS (2020)
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging
Julie Refardt et al.
ENDOCRINE-RELATED CANCER (2020)
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma
Tingting Feng et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast, Colorectal, or Lung Cancer (AFT-01, -02, -03)
Melisa L. Wong et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione et al.
NEUROENDOCRINOLOGY (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
Emanuele Leoncini et al.
ENDOCRINE (2017)
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
Sven-Petter Haugvik et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications
Nicola Fazio et al.
CANCER TREATMENT REVIEWS (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors
Zhi Rong Qian et al.
PANCREAS (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
Daniel Kaemmerer et al.
ONCOTARGET (2015)
Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas A Clinicopathologic Analysis of 44 Cases
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Clinicopathologic Characteristics of Pancreatic Neuroendocrine Tumors and Relation of Somatostatin Receptor Type 2A to Outcomes
Kosuke Okuwaki et al.
CANCER (2013)
Share Paper
